C o r e C The Administrative Core (Core C) provides leadership and administrative support for the planning, coordination, implementation and ongoing review of the individual research projects, cores and program of clinical trials to be conducted under the proposed Program Project. To foster the scientific and clinical objectives ofthe individual projeds and the Program Project as a whole, this core conducts periodic meetings with the participating principal investigators to develop strategic plans and consensual decisions regarding program development and organizes periodic reviews of research progress and productivity by external scientific advisory committees. This Core also provides direction and coordination for the activities of the transplant program's integrated data management. The core also maintains and facilitates communication between investigators in the individual projects and cores through weekly conferences and research-in-progress presentations. Lastly, this Core provides fiscal management services for the projects and cores of the Program Project, and provides critical analytic support for the preparation of research progress reports and interim analyses of clinical trials as required by the IRB, NMDP, NIH and, as applicable the FDA.
This Administrative Core provides scientific leadership and overall direction to the Program. This ensures appropriately frugal use of limited resources for maximal effect. This core also has and will continue to foster rapid translation of discoveries made in the Research Project into clinical trials and ultimate extension to the community.
|Ataie, Niloufar; Xiang, Jingyi; Cheng, Neal et al. (2016) Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics. J Mol Biol 428:194-205|
|Richardson, Paul G; Riches, Marcie L; Kernan, Nancy A et al. (2016) Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood 127:1656-65|
|Hasan, A N; Selvakumar, A; Shabrova, E et al. (2016) Soluble and membrane-bound interleukin (IL)-15 RÎ±/IL-15 complexes mediate proliferation of high-avidity central memory CD8(+) T cells for adoptive immunotherapy of cancer and infections. Clin Exp Immunol 186:249-265|
|Spitzer, Barbara; Perales, Miguel-Angel; Kernan, Nancy A et al. (2016) Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa. Biol Blood Marrow Transplant 22:1449-54|
|Park, Jae H; Geyer, Mark B; Brentjens, Renier J (2016) CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date. Blood 127:3312-20|
|Xiong, Huizhong; Keith, James W; Samilo, Dane W et al. (2016) Innate Lymphocyte/Ly6C(hi) Monocyte Crosstalk Promotes Klebsiella Pneumoniae Clearance. Cell 165:679-89|
|Jiang, Yanwen; Ortega-Molina, Ana; Geng, Huimin et al. (2016) CREBBP Inactivation Promotes the Development of HDAC3 Dependent Lymphomas. Cancer Discov :|
|Shono, Yusuke; Docampo, Melissa D; Peled, Jonathan U et al. (2016) Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med 8:339ra71|
|Hobbs, G S; Kaur, N; Hilden, P et al. (2016) A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation. Bone Marrow Transplant 51:1010-2|
|Huang, Yao-Ting; Neofytos, Dionysios; Foldi, Julia et al. (2016) Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 22:1480-6|
Showing the most recent 10 out of 392 publications